for OVX836, its Broad-Spectrum Influenza Vaccine.
• A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains
• Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers